Mumbai, October 23, 2026: Lupin Limited, a prominent global pharmaceutical company, has announced the appointment of Brian Savage as its President and Chief Legal Officer. In his new role, Savage will oversee Lupin’s global Legal, Compliance, and Intellectual Property Management Group (IPMG) functions, operating from New Jersey.
Brian Savage transitions to Lupin from Teva Pharmaceuticals, where he held several senior leadership positions since 2015. His most recent role at Teva was as Executive Vice President and Interim Global Chief Legal Officer. During his tenure, Savage was instrumental in shaping Teva’s global litigation strategy and served as General Counsel for its U.S. Generics business. Prior to his time at Teva, he practised law at Dechert LLP, bringing with him a wealth of experience in the legal and regulatory sectors of the pharmaceutical industry. Savage is an alumnus of Yale Law School, where he earned his Juris Doctor, and he graduated summa cum laude with a B.A. from the University of Pennsylvania.
Lupin’s CEO, Vinita Gupta, and Managing Director, Nilesh Gupta, expressed their enthusiasm regarding Savage’s appointment. They highlighted his comprehensive understanding of the pharmaceutical industry, his extensive legal expertise, and his leadership capabilities as crucial assets for Lupin. They believe his addition to the executive leadership team will significantly bolster the company’s governance framework, aid in navigating the evolving regulatory landscape, and support Lupin’s long-term growth objectives.
Lupin Limited, headquartered in Mumbai, India, is a leading figure in the global pharmaceutical industry, with a presence in over 100 markets. The company specialises in a wide array of pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. With a strong foothold in India and the U.S., Lupin operates across various therapeutic areas and maintains 15 manufacturing sites and six research centres worldwide. The company is supported by a workforce of over 26,000 professionals dedicated to enhancing patient health outcomes.
The appointment of Brian Savage is seen by analysts as a strategic move by Lupin to strengthen its legal and compliance framework, which is increasingly important in the highly regulated pharmaceutical industry. This leadership change is expected to provide Lupin with a competitive edge as it continues to expand its global footprint.
